Director and 10% owner David P. Bonita filed a Form 4 with the SEC on November 18, 2026, disclosing multiple transactions in the common shares of Windward Bio Group AG (NASDAQ:WWB) on November 16, 2026, primarily in connection with the company's initial public offering.

Key Highlights

  • IPO purchase: Bonita acquired 1,176,471 common shares at $17.00 per share in the issuer's initial public offering on November 16, 2026.
  • Preferred share conversions: 3,561,936 Series A Preferred Shares and 1,611,008 Series B Preferred Shares each converted automatically into common shares on a 1-to-1 basis immediately prior to the IPO closing.
  • Warrant exercise: 216,668 fully vested warrants were exercised (transaction code M) at an exercise price of $0.02 per share, with an expiration date of May 12, 2036.
  • Shares withheld: 232 common shares were withheld (transaction code F) at $17.00 per share in connection with the warrant exercise.
  • Resulting ownership: Following all reported transactions, Bonita's indirectly held common shares totaled 7,097,483, all held of record by OrbiMed Private Investments IX, LP.
  • Stock options granted: Bonita holds 22,675 stock options with an exercise price of $17.00, vesting in 12 equal monthly installments beginning December 31, 2026, held directly.

Bonita's IPO-Day Transactions in Windward Bio Group AG Common Shares

According to the filing, all of the reported non-derivative and derivative transactions occurred on November 16, 2026, coinciding with the issuer's initial public offering. Bonita acquired 1,176,471 common shares at $17.00 per share in that offering. Separately, 3,561,936 Series A Preferred Shares and 1,611,008 Series B Preferred Shares held indirectly converted automatically into common shares on a 1-to-1 basis immediately prior to the IPO closing, reducing the derivative security positions for both series to zero following conversion.

The filing also reports the exercise of 216,668 fully vested warrants at an exercise price of $0.02 per share. The filing states that the exercise price "reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors." In connection with that warrant exercise, 232 common shares were withheld. After all five reported transactions, the indirectly held common share total stood at 7,097,483.

All indirectly held common shares are held of record by OrbiMed Private Investments IX, LP. The filing notes that OrbiMed Capital GP IX LLC is the general partner of that fund and that OrbiMed Advisors LLC is its managing member. Bonita is identified as a member of OrbiMed Advisors. The filing states that Bonita "disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act," except to the extent of any pecuniary interest. Additionally, the filing reports 22,675 directly held stock options with an exercise price of $17.00, which will vest in 12 equal monthly installments on the last day of each month beginning December 31, 2026, subject to Bonita's continuous service.

What Was Disclosed

This Form 4 covers five transactions by director and 10% owner David P. Bonita in Windward Bio Group AG common shares on November 16, 2026, including an IPO purchase, two preferred share conversions, a warrant exercise, and a share withholding, plus a stock option grant.